Clinical Trial

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

Study acronym: PEMBROCABOSARC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-12-20; most recent amendment 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2022-07-27
Trial Details
NCT Number NCT05182164
Lead Sponsor Institut Bergonié
Collaborators: Ipsen, MSD France
Conditions Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic Sarcoma
Enrollment 119 participants
Start Date 2022-04-25
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-07